Skip to content

Interest Income at other companies

Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$2.57M+15.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$5.32M-18.3%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$12.66M-14.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$6M-14.3%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$6.91M-14.5%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s interest income?
MBX Biosciences, Inc. (MBX) reported interest income of $3.75M in Q1 2026.
How has MBX Biosciences, Inc.'s interest income changed year-over-year?
MBX Biosciences, Inc.'s interest income increased by 41.5% year-over-year, from $2.65M to $3.75M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.